Literature DB >> 30066919

Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis.

Yu-Di Zhu1, Ming-Yue Lu2.   

Abstract

Despite advances in management, bladder cancer remains a principal cause of cancer‑associated complications. Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) is dysregulated in certain types of cancer; however, limited data are available on the expression and function of TNFRSF14 in bladder cancer. In the present study, the aim was to evaluate the expression and biological functions of TNFRSF14 in bladder cancer. Firstly, the expression levels of TNFRSF14 in bladder cancer tissue were examined using The Cancer Genome Atlas (TCGA) database. Secondly, reverse transcription‑quantitative polymerase chain reaction was utilized to investigate the expression levels of TNFRSF14 in the T24, SW780 and EJ‑M3 bladder cancer cell lines. Transfection and Cell Counting kit‑8 (CCK‑8) assay was used to evaluate whether TNFRSF14 overexpression or silencing would have an effect on cell proliferation of T24 and EJ‑M3 cells. In addition, TNFRSF14‑induced apoptotic cells were identified using Annexin V‑fluorescein isothiocyanate and propidium iodide staining. Western blot analysis was used to detect proteins associated with the phosphatidylinositol 3‑kinase pathway. According to the TCGA dataset, the expression levels TNFRSF14 were decreased in bladder cancer tissue compared with in normal control samples. Patients with bladder cancer exhibiting low expression levels of TNFRSF14 had a worse prognosis compared to those with high expression levels of TNFRSF14. Overexpression of TNFRSF14 in T24 cells led to increased apoptosis and inhibited cell proliferation in vitro. Western blotting demonstrated that TNFRSF14 overexpression increased the expression levels of caspase3p17 in T24 cells, but significantly decreased the expression levels of phosphorylated (p)‑protein kinase B (AKT) and P70 S6 kinase (P70). TNFRSF14 silencing in EJ‑M3 cells enhanced cell growth, inhibited cell apoptosis, increased the expression levels of p‑AKT and P70, and decreased the expression levels of caspase3p17. In conclusion, TNFRSF14 may serve a tumor suppressive role in bladder cancer by inducing apoptosis and suppressing proliferation, and act as a novel prognostic biomarker for bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30066919     DOI: 10.3892/mmr.2018.9306

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.

Authors:  Chengquan Shen; Jing Liu; Jirong Wang; Xiaokun Yang; Haitao Niu; Yonghua Wang
Journal:  Dis Markers       Date:  2020-05-13       Impact factor: 3.434

2.  HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.

Authors:  Nausicaa Malissen; Nicolas Macagno; Samuel Granjeaud; Clémence Granier; Vincent Moutardier; Caroline Gaudy-Marqueste; Nadia Habel; Marion Mandavit; Bernard Guillot; Christine Pasero; Eric Tartour; Robert Ballotti; Jean-Jacques Grob; Daniel Olive
Journal:  Oncoimmunology       Date:  2019-09-25       Impact factor: 8.110

3.  A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer.

Authors:  Yuhan Sun; Alexander James Sedgwick; Md Abdullah-Al-Kamran Khan; Yaseelan Palarasah; Stefano Mangiola; Alexander David Barrow
Journal:  Front Immunol       Date:  2021-11-10       Impact factor: 7.561

4.  Identification of Immune-Related Genes Associated With Bladder Cancer Based on Immunological Characteristics and Their Correlation With the Prognosis.

Authors:  Zhen Kang; Wei Li; Yan-Hong Yu; Meng Che; Mao-Lin Yang; Jin-Jun Len; Yue-Rong Wu; Jun-Feng Yang
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

5.  Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.

Authors:  Linhui Wang; Yutao Wang; Jianfeng Wang; Luanfeng Li; Jianbin Bi
Journal:  J Immunol Res       Date:  2021-10-18       Impact factor: 4.818

6.  Single-Cell Sequencing Unveils the Heterogeneity of Nonimmune Cells in Chronic Apical Periodontitis.

Authors:  Xinwei Lin; Danlu Chi; Qingzhen Meng; Qimei Gong; Zhongchun Tong
Journal:  Front Cell Dev Biol       Date:  2022-02-10

7.  The Pyroptosis-Related Risk Genes APOBEC3D, TNFRSF14, and RAC2 Were Used to Evaluate Prognosis and as Tumor Suppressor Genes in Breast Cancer.

Authors:  Qian Chen; He Jun; ChengGuang Yang; Feng Yang; YingJie Xu
Journal:  J Oncol       Date:  2022-08-25       Impact factor: 4.501

8.  A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients.

Authors:  Zesi Liu; Hongxia Yang; Ziyu Chen; Chunli Jing
Journal:  Hereditas       Date:  2022-10-18       Impact factor: 2.595

9.  c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.

Authors:  Antonin Bouroumeau; Lucile Bussot; Thierry Bonnefoix; Cyril Fournier; Caroline Chapusot; Olivier Casasnovas; Laurent Martin; Anne McLeer; Edwige Col; Laurence David-Boudet; Christine Lefebvre; Caroline Algrin; Tatiana Raskovalova; Marie-Christine Jacob; Claire Vettier; Simon Chevalier; Mary B Callanan; Rémy Gressin; Anouk Emadali; Hervé Sartelet
Journal:  J Pathol Clin Res       Date:  2021-08-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.